Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764125 | 0.80 | CYP2D6 (0.37) | EPHX1CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL23696755 | 0.80 | EPHX1 (0.47) | EPHX1CYP2D6CYP2C19 | |
| SCHEMBL25110744 | 0.78 | EPHX1 (0.50) | EPHX1 | |
| SCHEMBL23468512 | 0.78 | HRH4 (0.33) | HRH4HRH3 | |
| SCHEMBL21291218 | 0.78 | EPHX1 (0.44) | EPHX1CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL19170920 | 0.77 | PAOX (0.38) | EPHX1CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL21291261 | 0.76 | CYP2D6 (0.37) | EPHX1CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL21291175 | 0.76 | CYP2D6 (0.37) | EPHX1CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL9624660 | 0.76 | HRH4 (0.47) | EPHX1HRH4HRH3CYP2D6CYP2C19 | |
| SCHEMBL641327 | 0.74 | CYP2D6 (0.36) | EPHX1HRH4HRH3CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX1 1684/4885HRH4 3886/4885HRH3 3631/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX1 1684/4885HRH4 3886/4885HRH3 3631/4885 |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX1 1684/4885HRH4 3886/4885HRH3 3631/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX1 1684/4885HRH4 3886/4885HRH3 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.